Drugs / BMS-986258
last change Aug 2024 re-read 2 minutes ago

BMS-986258

Developed for
cancer of unknown primary site
Investigated by
Bristol-Myers Squibb

Trials 1 · a red edge is where a trial was stopped

201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT03446040 Mar 2018 → Aug 2024 cancer of unknown primary site Bristol-Myers Squibb Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as BMS-986258 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03446040
Known as Anti-tim-3 antibody bms-986258 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297708
Known as ONO-7807 ChEMBL registry synonym — accepted as the source's own label CHEMBL4297708